Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Domain Therapeutics Enters into Collaboration with XOMA

Published: Wednesday, February 05, 2014
Last Updated: Wednesday, February 05, 2014
Bookmark and Share
DTect-All™ platform will be used to screen for GPCR-directed allosteric modulator antibodies.

Domain Therapeutics has announced that it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.

XOMA, a California based U.S. public company, focuses its research on allosteric modulation which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.

Domain Therapeutics has extensive expertise in allosteric modulation and operates DTect-All™, a platform that has successfully discovered small molecule allosteric modulators for a wide range of GPCRs.

Domain Therapeutics and XOMA will jointly evaluate the robustness of DTect-All to identify allosteric modulator antibodies of a first target. If successful, the partners may elect to further collaborate on other GPCRs from a set of preselected targets for which, under the terms of the agreement, Domain Therapeutics will be eligible for an upfront payment and certain undisclosed milestones per target, as well as undisclosed royalties. Domain will have the right to offer its DTect-All platform to discover antibody-based drugs to other companies outside the scope of the set of GPCRs selected by XOMA.

“We strongly believe that XOMA is the partner of choice to discover allosteric modulator antibodies targeting GPCRs and that applying DTect-All to this area of research will represent a real breakthrough,” said Pascal Neuville, board director and CEO of Domain Therapeutics. “We anticipate that this collaboration will enhance our drug discovery capabilities by opening the door to other biologics. It will further strengthen Domain Therapeutics’ position as a key player in GPCR drug discovery.”

The therapeutic antibodies market is expected to grow from USD 45 billion in 2011 to USD 58 billion in 2016 (BCC Research, 2012). GPCRs, as a major class of therapeutic targets, are expected to be a large part of it if technology obstacles can be overcome.

The current paradigm of GPCR-targeting antibody discovery relies on screening techniques lacking robustness and reproducibility making the process very challenging and resulting in the failure of many discovery programs.

So far, just one GPCR antibody product has reached the market, however, a pipeline of Phase II candidates does confirm strong interest by the pharmaceutical industry.

Allosteric modulator antibodies are expected to display superior selectivity and safety over classic GPCR drugs. Domain’s technology has the potential to overcome the limitations of other technologies to discover this class of antibodies with novel mode of action.

The majority of ongoing GPCR antibody discovery and development programs are dedicated to the identification of antagonist entities, which induce an inhibition of the GPCR signaling.

By facilitating access to this new category of drugs, DTect-All will generate differentiated and valuable assets for companies like XOMA, who are developing GPCR-targeting antibodies.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domain Therapeutics Appoints Professor Michel Bouvier
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs.
Tuesday, September 23, 2014
Domain Therapeutics Opens a North American Subsidiary at Montreal's NEOMED Institute
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All™ technology.
Tuesday, January 21, 2014
Domain Therapeutics, Universite de Montreal, IRICoR and McGill University Sign Agreement
New licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.
Thursday, December 26, 2013
Domain Therapeutics and Ono Sign Collaboration Agreement
Collaboration agreement in the field of GPCR-based drug discovery.
Tuesday, October 23, 2012
Domain Therapeutics Closes EUR Two Million Funding Round
The funds will enable the company to strengthen its position as a strategic collaborative partner to the pharmaceutical industry for discovering drugs targeting GPCRs.
Wednesday, July 18, 2012
Domain Therapeutics Wins EUR 933,000 Grant for Schizophrenia Project
GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapies.
Wednesday, March 14, 2012
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease.
Monday, January 17, 2011
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!